시장보고서
상품코드
1975281

DNA 진단 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

Global DNA Diagnostics Market Size, Share, Trends & Growth Analysis Report 2026-2034

발행일: | 리서치사: 구분자 Value Market Research | 페이지 정보: 영문 198 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

DNA 진단 시장 규모는 2025년 188억 1,000만 달러에서 2026년부터 2034년까지 CAGR 9.64%로 성장하여 2034년에는 430억 7,000만 달러에 달할 것으로 예측됩니다.

세계 DNA 진단 시장은 정밀의료, 질병 조기발견, 유전자 스크리닝에 대한 수요 증가를 배경으로 크게 확대되고 있습니다. 유전성 질환, 암, 감염성 질환의 유병률 증가는 분자진단 기술의 채택을 가속화하고 있습니다. 차세대 염기서열 분석(NGS), PCR 기반 검사, CRISPR 기반 진단 플랫폼의 발전으로 정확도와 소요 시간이 개선되고 있습니다. 맞춤형 치료 접근법과 예방의학에 대한 인식이 높아지면서 선진국과 신흥 경제권에서 시장 침투가 더욱 가속화되고 있습니다.

주요 성장 요인으로는 신생아 선별검사 프로그램 확대, 유전체 연구에 대한 투자 증가, 유전자 데이터 분석에 인공지능(AI)의 통합 등을 꼽을 수 있습니다. 제약기업들은 동반진단 및 표적 치료제 개발에 있어 DNA 진단기술의 활용을 강화하고 있습니다. 또한, 시퀀싱 비용의 하락과 검사실 자동화의 발전으로 고급 유전자 검사에 대한 접근성이 향상되고 있습니다. 유전체 연구와 집단 건강 검진 프로그램을 장려하는 정부 정책은 규제 및 자금 조달 측면에서 유리한 환경을 조성하고 있습니다.

향후 전망으로는 종양학, 희귀질환, 생식의학, 약물유전학 분야에서의 응용 확대가 시장 성장에 기여할 것으로 예상됩니다. 가정용 유전자 검사 키트와 소비자 직접 검사 서비스로의 전환은 산업 구조를 재편할 가능성이 있습니다. 생명공학 기업, 연구기관, 의료 서비스 제공자 간의 전략적 협력이 혁신을 가속화할 것입니다. 맞춤형 의료가 주류가 되는 가운데, DNA 진단은 전 세계적으로 예측의료, 예방의료, 정밀의료 모델의 핵심으로 자리 잡을 것으로 보입니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 DNA 진단 시장 : 제공별

제5장 세계의 DNA 진단 시장 : 기술별

제6장 세계의 DNA 진단 시장 : 용도별

제7장 세계의 DNA 진단 시장 : 검체별

제8장 세계의 DNA 진단 시장 : 최종사용자별

제9장 세계의 DNA 진단 시장 : 지역별

제10장 경쟁 구도

제11장 기업 개요

KSM 26.04.03

The DNA Diagnostics Market size is expected to reach USD 43.07 Billion in 2034 from USD 18.81 Billion (2025) growing at a CAGR of 9.64% during 2026-2034.

The Global DNA Diagnostics Market is witnessing strong expansion driven by rising demand for precision medicine, early disease detection, and genetic screening. Increasing prevalence of hereditary disorders, cancer, and infectious diseases has accelerated the adoption of molecular diagnostic technologies. Advancements in next-generation sequencing (NGS), PCR-based testing, and CRISPR-based diagnostic platforms are improving accuracy and turnaround time. Growing awareness regarding personalized treatment approaches and preventive healthcare is further supporting market penetration across developed and emerging economies.

Key growth drivers include expanding newborn screening programs, increasing investments in genomics research, and the integration of artificial intelligence in genetic data interpretation. Pharmaceutical companies are increasingly leveraging DNA diagnostics for companion diagnostics and targeted drug development. Moreover, declining sequencing costs and improved laboratory automation are making advanced genetic tests more accessible. Government initiatives promoting genomic research and population health screening programs are creating favorable regulatory and funding environments.

Looking ahead, the market is expected to benefit from expanding applications in oncology, rare diseases, reproductive health, and pharmacogenomics. The shift toward home-based genetic testing kits and direct-to-consumer testing services is likely to reshape industry dynamics. Strategic collaborations between biotechnology firms, research institutes, and healthcare providers will accelerate innovation. As personalized healthcare becomes mainstream, DNA diagnostics will remain central to predictive, preventive, and precision medicine models worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Offering

  • Instruments
  • Reagents & Kits
  • Services & Software

By Technology

  • In Situ Hybridization
  • Mass Spectroscopy
  • Microarrays
  • Polymerase Chain Reaction (PCR)
  • Sequencing
  • Others

By Application

  • Cancer Genetics Tests
  • Infectious Diseases DNA Testing
  • Newborn Genetic Screening
  • Preimplantation & Reproductive Diagnosis
  • Non-Infectious Diseases DNA Testing
  • Hematology & Immunology/Identity Diagnostics & Forensics
  • Pharmacogenomics/Drug Metabolism
  • Prenatal DNA Carrier Screening
  • Others

By Specimen

  • Blood, Serum, and Plasma
  • Urine
  • Others

By End User

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Others

COMPANIES PROFILED

  • Abbott Laboratories, Agilent Technologies Inc, Avalon GloboCare Corp, Beckman Coulter Inc, BioRad Laboratories Inc, Cepheid, F HoffmannLa Roche Ltd, GE HealthCare Technologies Inc, Hologic Inc, Illumina Inc, Siemens Healthineers formerly Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL DNA DIAGNOSTICS MARKET: BY OFFERING 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Offering
  • 4.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Reagents & Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Services & Software Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DNA DIAGNOSTICS MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Technology
  • 5.2. In Situ Hybridization Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Mass Spectroscopy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Microarrays Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Polymerase Chain Reaction (PCR) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DNA DIAGNOSTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Application
  • 6.2. Cancer Genetics Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Infectious Diseases DNA Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Newborn Genetic Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Preimplantation & Reproductive Diagnosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Non-Infectious Diseases DNA Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.7. Hematology & Immunology/Identity Diagnostics & Forensics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.8. Pharmacogenomics/Drug Metabolism Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.9. Prenatal DNA Carrier Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.10. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DNA DIAGNOSTICS MARKET: BY SPECIMEN 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Specimen
  • 7.2. Blood, Serum, and Plasma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Urine Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL DNA DIAGNOSTICS MARKET: BY END USER 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast End User
  • 8.2. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL DNA DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Offering
    • 9.2.2 By Technology
    • 9.2.3 By Application
    • 9.2.4 By Specimen
    • 9.2.5 By End User
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Offering
    • 9.3.2 By Technology
    • 9.3.3 By Application
    • 9.3.4 By Specimen
    • 9.3.5 By End User
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Offering
    • 9.4.2 By Technology
    • 9.4.3 By Application
    • 9.4.4 By Specimen
    • 9.4.5 By End User
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Offering
    • 9.5.2 By Technology
    • 9.5.3 By Application
    • 9.5.4 By Specimen
    • 9.5.5 By End User
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 South East Asia
    • 9.5.11 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Offering
    • 9.6.2 By Technology
    • 9.6.3 By Application
    • 9.6.4 By Specimen
    • 9.6.5 By End User
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL DNA DIAGNOSTICS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Abbott Laboratories
    • 11.2.2 Agilent Technologies Inc
    • 11.2.3 Avalon GloboCare Corp
    • 11.2.4 Beckman Coulter Inc
    • 11.2.5 Bio-Rad Laboratories Inc
    • 11.2.6 Cepheid
    • 11.2.7 F. Hoffmann-La Roche Ltd
    • 11.2.8 GE HealthCare Technologies Inc
    • 11.2.9 Hologic Inc
    • 11.2.10 Illumina Inc
    • 11.2.11 Siemens Healthineers (Formerly Siemens Healthcare Private Limited)
    • 11.2.12 Thermo Fisher Scientific Inc
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제